IGFBP7 and acute kidney injury: Recently, the results of the PrevAKI multicenter trial confirmed once again that the [TIMP-2] × [IGFBP7]-guided implementation of a simple care bundle consisting of the optimization of volume status and hemodynamics, functional hemodynamic monitoring, the avoidance of nephrotoxic drugs, and the prevention of hyperglycemia effectively reduced the incidence of stage 2 and 3 AKI in comparison to the control group (14.0% vs. 23.9%; ARR 10.0% (95% CI, 0.9–19.1); P = 0.034) [60].